Press release
Paris, December 6, 2021
Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar. Quantum Genomics will receive up to $20 M
06.12.2021 - Quantum Genomics will receive up to $20 M in upfront, development and sales milestone payments as well as royalties on future salesJulphar will receive an exclusive license to market firibastat in the Middle East, all African countries, Commonwealth . Seite 1
Quantum Genomics will receive up to $20 M in upfront, development and sales milestone payments as well as royalties on future salesJulphar will receive an.
Gulf Pharmaceutical Industries (Julphar) has announced the signing of an exclusive license and production agreement with Quantum Genomics, a leading biopharmaceutica.
Share:
PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE)
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure today announced the launch of its Phase III REFRESH study in difficult-to-treat
(
(2) hypertension.
This new study is part of firibastat s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients. We are thrilled to launch this new pivotal study as a precursor to potential market approval of single dose firibastat, which we believe to be the best regimen for chronic treatment of resistant of difficult-to-treat hypertension, said Jean-Philippe Milon, Chief Executive Officer at Quantum Genomics.